0JZU Stock Chart & Stats
$835.65
$18.94(2.27%)
At close: 4:00 PM EDT
$835.65
$18.94(2.27%)
Day’s Range― - ―
52-Week Range$710.01 - $1,034.85
Previous CloseN/A
Volume69.00
Average Volume (3M)257.00
Market Cap
$114.36B
Enterprise Value$99.45B
Total Cash (Recent Filing)$5.16B
Total Debt (Recent Filing)$11.70B
Price to Earnings (P/E)26.1
Beta0.46
Next Earnings
Nov 04, 2026EPS Estimate
10.72Next Dividend Ex-DateN/A
Dividend Yield0.35%
Share Statistics
EPS (TTM)37.53
Shares Outstanding116,590,360
10 Day Avg. Volume400
30 Day Avg. Volume257
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)-49.24
Price to Sales (P/S)0.27
P/FCF Ratio19.77
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue0.24
Enterprise Value/Gross Profit6.65
Enterprise Value/Ebitda13.55
Forecast
1Y Price Target
$1,021.50Price Target Upside22.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)44.64
Revenue Forecast (FY)$431.92B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationMcKesson converts earnings into substantial cash, giving the business resilience despite its low-margin distribution model. Strong operating and free cash flow can fund technology, logistics, strategic investments, debt service, and shareholder returns over the next several quarters.
Broad-based Operating GrowthRaised guidance indicates that growth is supported across multiple operating areas rather than by a single product or customer group. Oncology, pharmaceuticals, and prescription technology each contribute expansion, improving business diversification and supporting durable earnings momentum.
Expansion Into Specialty CareThe planned Option Care transaction would deepen McKesson’s presence in specialty therapies and community-based infusion care, adding exposure to a growing healthcare delivery model. Its national footprint and technology-driven platform could broaden long-term service capabilities after closing.
Bears Say
Negative Shareholders’ EquityPersistent negative equity is a structural balance-sheet weakness that reduces financial flexibility and makes conventional leverage signals harder to interpret. Although assets and liquidity are substantial, this capital structure leaves less protection against downturns, restructuring costs, or weaker cash generation.
Thin, Compressed MarginsMcKesson’s distribution economics depend on very high volume because profitability per dollar of revenue is limited. Margin compression increases sensitivity to pricing, product mix, reimbursement, and execution, so modest operating pressure could have an outsized effect on earnings and cash returns.
MedSurg Profitability PressureThe MedSurg segment is producing weaker profit conversion even while revenue grows, reflecting unfavorable product mix and administrative costs. Continued pressure would dilute consolidated operating leverage, while the separation and related financing may add complexity before the business reaches a more stable standalone profile.
McKesson News
0JZU FAQ
What was Mckesson Corp.’s price range in the past 12 months?
Mckesson Corp. lowest share price was $710.01 and its highest was $1034.85 in the past 12 months.
What is Mckesson Corp.’s market cap?
Mckesson Corp.’s market cap is $114.36B.
When is Mckesson Corp.’s upcoming earnings report date?
Mckesson Corp.’s upcoming earnings report date is Nov 04, 2026 which is in 5 days.
How were Mckesson Corp.’s earnings last quarter?
Mckesson Corp. released its earnings results on Aug 05, 2026. The company reported $9.93 earnings per share for the quarter, beating the consensus estimate of $9.561 by $0.369.
Is Mckesson Corp. overvalued?
According to Wall Street analysts Mckesson Corp.’s price is currently Undervalued.
Does Mckesson Corp. pay dividends?
Mckesson Corp. pays a Quarterly dividend of $0.94 which represents an annual dividend yield of 0.35%. See more information on Mckesson Corp. dividends here
What is Mckesson Corp.’s EPS estimate?
Mckesson Corp.’s EPS estimate is 10.72.
How many shares outstanding does Mckesson Corp. have?
Mckesson Corp. has 116,590,360 shares outstanding.
What happened to Mckesson Corp.’s price movement after its last earnings report?
Mckesson Corp. reported an EPS of $9.93 in its last earnings report, beating expectations of $9.561. Following the earnings report the stock price went up 1.583%.
Which hedge fund is a major shareholder of Mckesson Corp.?
Currently, no hedge funds are holding shares in GB:0JZU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
McKesson Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,021.50 (22.24% Upside)
$1,021.50 (22.24% Upside)
Blogger Sentiment
Neutral
GB:0JZU Sentiment 58%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth $268.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.92%
12-Months-Change
Fundamentals
Return on Equity
-194.39%
Trailing 12-Months
Asset Growth
8.63%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mckesson Corp.
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
0JZU Company Deck
0JZU Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operational momentum: double-digit EPS growth, an 8% revenue increase to $105.4B, broad-based segment strength (notably Oncology & Multispecialty and North American Pharmaceuticals), improved gross profit and operating leverage, a raised full-year EPS guide, active capital returns (large buyback and dividend increase), and continued strategic progress on the MedSurg separation and tech/AI initiatives. Lowlights included a quarterly negative free cash flow readout (seasonal but improved vs prior year), a 20% decline in MedSurg operating profit, financing-related interest expense and GAAP remeasurement charges, and macro/regulatory uncertainties (WAC reductions, branded-to-generic conversions, 340B/IRA policy risks). Overall, the positive operational and financial beats and raised guidance materially outweigh the noted one-offs, financing costs, and policy risks.View all GB:0JZU earnings summaries0JZU Revenue Breakdown
83.45% North American Pharmaceutical
12.00% Oncology & Multispecialty
1.44% Prescription Technology Solutions
2.85% Medical-Surgical Solutions
0.26% Other
0JZU Stock 12 Month Forecast
Average Price Target
$1,021.50
▲(22.24% Upside)
Technical Analysis
Cencora
―
Cardinal Health
―
Henry Schein
―
Prestige Consumer Healthcare
―
Guardian Pharmacy Services, Inc. Class A
―